Olympus Corp. (JP:7733)
:7733
Want to see JP:7733 full AI Analyst Report?
7733 Stock Chart & Stats
¥1583.50
¥60.50(2.58%)
At close: 4:00 PM EST
¥1583.50
¥60.50(2.58%)
Day’s Range― - ―
52-Week Range¥1,302.50 - ¥2,168.00
Previous CloseN/A
Volume4.23M
Average Volume (3M)3.67M
Market Cap
¥1.92T
Enterprise Value¥2.02T
Total Cash (Recent Filing)¥188.04B
Total Debt (Recent Filing)¥239.58B
Price to Earnings (P/E)28.0
Beta0.81
Next Earnings
Aug 12, 2026EPS Estimate
9.94Next Dividend Ex-DateN/A
Dividend Yield1.01%
Share Statistics
EPS (TTM)61.37
Shares Outstanding1,114,485,700
10 Day Avg. Volume4,971,740
30 Day Avg. Volume3,665,053
Financial Highlights & Ratios
PEG Ratio-0.60
Price to Book (P/B)2.04
Price to Sales (P/S)1.64
P/FCF Ratio36.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥2,125.00Price Target Upside34.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)89.2
Revenue Forecast (FY)¥1.06T
Bulls Say, Bears Say
Bulls Say
Steady Revenue GrowthSustained multi-year top-line growth indicates durable demand for Olympus' endoscopy systems and consumables, supporting a growing installed base and recurring revenue streams. This stability underpins long-term investment in product refresh cycles and service contracts.
High Gross MarginsConsistently high gross margins reflect strong product differentiation and pricing power in medical imaging and endoscopy. These margins provide structural capacity to absorb R&D and support service networks while preserving profitability through equipment lifecycle sales and consumables.
Strengthened Balance SheetMaterial reduction in leverage and a larger equity base improve financial flexibility for R&D, targeted M&A, and capital spending cycles. A stronger balance sheet lowers bankruptcy risk and supports sustained investments across product and service lines.
Bears Say
2026 Margin CompressionA significant drop in net margin signals cost pressure, mix shifts, or higher operating expenses that compress earnings power. If structural, reduced margins limit reinvestment capacity, weaken free cash generation, and constrain long-term profitability resilience.
Volatile Free Cash FlowLarge FCF volatility and weaker cash conversion (OCF covering only a modest portion of earnings; FCF < half of net income) impair consistent capital allocation, increase reliance on external funding in weak years, and raise execution risk for long-term projects.
Uneven Profitability / ROEFluctuating returns on equity suggest earnings are influenced by cyclical or one-off factors rather than steady operational improvement. This reduces predictability of shareholder returns and complicates long-term performance forecasting and capital allocation.
Olympus News
7733 FAQ
What was Olympus Corp.’s price range in the past 12 months?
Olympus Corp. lowest stock price was ¥1302.50 and its highest was ¥2168.00 in the past 12 months.
What is Olympus Corp.’s market cap?
Olympus Corp.’s market cap is ¥1.92T.
When is Olympus Corp.’s upcoming earnings report date?
Olympus Corp.’s upcoming earnings report date is Aug 12, 2026 which is in 61 days.
How were Olympus Corp.’s earnings last quarter?
Olympus Corp. released its earnings results on May 12, 2026. The company reported ¥22.45 earnings per share for the quarter, beating the consensus estimate of ¥7.648 by ¥14.802.
Is Olympus Corp. overvalued?
According to Wall Street analysts Olympus Corp.’s price is currently Undervalued.
Does Olympus Corp. pay dividends?
Olympus Corp. pays a Annually dividend of ¥37 which represents an annual dividend yield of 1.01%. See more information on Olympus Corp. dividends here
What is Olympus Corp.’s EPS estimate?
Olympus Corp.’s EPS estimate is 9.94.
How many shares outstanding does Olympus Corp. have?
Olympus Corp. has 1,114,485,700 shares outstanding.
What happened to Olympus Corp.’s price movement after its last earnings report?
Olympus Corp. reported an EPS of ¥22.45 in its last earnings report, beating expectations of ¥7.648. Following the earnings report the stock price went down -0.677%.
Which hedge fund is a major shareholder of Olympus Corp.?
Currently, no hedge funds are holding shares in JP:7733
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Olympus Corp.
Olympus Corporation, a global enterprise headquartered in Tokyo, Japan, manufactures and distributes high-precision machinery and instrumentation worldwide. The company, originally established in 1919 as Olympus Optical Co., Ltd., adopted its current name in October 2003. Its extensive operations are structured into four primary divisions: Endoscopic Solutions, Therapeutic Solutions, Scientific Solutions, and a segment designated as "Others." The Endoscopic Solutions division specializes in developing and providing gastrointestinal and surgical endoscopes, comprehensive endoscopy systems, and associated repair services. The Therapeutic Solutions segment focuses on products for urology, gynecology, and ear, nose, and throat (ENT) procedures, alongside endo-therapy devices, energy-based surgical tools, and disposable surgical instruments. Within Scientific Solutions, Olympus supplies biological and industrial microscopes, industrial endoscopes and videoscopes, non-destructive testing (NDT) equipment, and X-ray fluorescence (XRF) analyzers. The "Others" segment encompasses biomedical materials and orthopedic equipment. Beyond these core areas, the company also offers a broader array of medical devices, including surgical microscopes, endoscope reprocessing units, electrosurgical tools, and respiratory-endotherapy devices, complemented by system integration and ongoing maintenance services.
7733 Company Deck
7733 Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Negative
The call presented a mix of significant near-term challenges—most notably product ship holds, FDA observations, one-off costs that reduced gross margin and a 2% revenue guidance downgrade—balanced against clear remediation plans, leadership actions, a majority of held products already released (70%), an asserted China recovery (≈5–6%), maintained midterm targets and a commitment to >100 bps margin expansion beginning FY2027. Near-term financial impact is material, but management articulated specific corrective actions and kept long-term targets unchanged.View all JP:7733 earnings summaries7733 Stock 12 Month Forecast
Average Price Target
¥2,125.00
▲(34.20% Upside)
Technical Analysis
Options Prices
Currently, No data available
---